Lamotrigine is an antiepileptic (sodium channel blocker) indicated for epilepsy and maintenance treatment of bipolar I disorder. We supply it to US manufacturers of tablets, chewable dispersible tablets, orally disintegrating tablets and extended-release tablets.
Data from PubChem (CID 3878) and FDA’s substance registry
CAS number
84057-84-1
Molecular formula
C9H7Cl2N5
Molecular weight
256.1g/mol
FDA UNII
IUPAC name
6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine
InChIKey
PYZRQGJRPPTADH-UHFFFAOYSA-N
- Appearance
- White to pale cream-colored powder.
- Solubility
- Very slightly soluble in water (0.17 mg/mL at 25 °C) and slightly soluble in 0.1 M hydrochloric acid (4.1 mg/mL at 25 °C).
Typical description, from FDA-approved labeling and pharmacopoeial monographs. The specification sent with your quote is the controlling document for any source.
Worth settling with your inquiry
Particle size matters most for orally disintegrating, chewable and extended-release products.
On the US market
- Reference product
- LamictalNDA 020241
- Approved ANDAs
- 37 with a marketed product
- Approved forms and strengths
- Extended-release tablet 25 mg, 50 mg, 100 mg, 200 mg, 250 mg, 300 mg
- Tablet 2 mg to 250 mg, in 8 strengths
- Orally disintegrating tablet 25 mg, 50 mg, 100 mg, 200 mg
- Tablet for oral suspension 2 mg, 5 mg, 25 mg
Single-ingredient products in FDA’s Drugs@FDA database, retrieved November 2026. The brand name belongs to its owner and identifies the reference product only.
Grade
USP or Ph. Eur. where a monograph exists, or your own specification.
Quantities
From development quantities for formulation work to commercial supply.
Packaging
To the manufacturer’s standard, typically fiber or HDPE drums with double polyethylene liners.
Regulatory filings
US DMF and CEP availability depends on the source. We confirm the filing status in writing with the quotation.
Documents available with a quote
- Specification and certificate of analysis
- Safety data sheet
- Method of analysis
- DMF letter of authorization, where a US DMF is filed
- GMP certificate and inspection history of the site
- Residual solvents and elemental impurities statements
- Nitrosamine risk assessment
- TSE/BSE statement
Need something else for your QA file? Email info@yogpharma.com
Sertraline Hydrochloride
Selective serotonin reuptake inhibitor (SSRI)
CAS 79559-97-0Escitalopram Oxalate
Selective serotonin reuptake inhibitor (SSRI)
CAS 219861-08-2Duloxetine Hydrochloride
Serotonin-norepinephrine reuptake inhibitor (SNRI)
CAS 136434-34-9Bupropion Hydrochloride
Norepinephrine-dopamine reuptake inhibitor
CAS 31677-93-7